Latest Administration News

Highfield Resources progresses its strategic partnership with Yankuang Energy, securing key regulatory approvals and updating financing arrangements for the Muga Potash mine, while navigating a court ruling on a mining concession.

InteliCare advances its AI-driven platform deployment across multiple Hardi Aged Care sites, while expanding its commercial pipeline and enhancing product capabilities.

InteliCare Holdings Limited reported a positive net cash flow of $30,000 for the December quarter, buoyed by a substantial government R&D rebate. The company ends the quarter with $1.26 million in cash, signaling operational stability amid ongoing funding evaluations.

Charger Metals NL's December quarter cash flow report reveals a $800,000 net cash decrease, driven by sustained exploration spending and limited operating receipts, leaving the company with $2.49 million in cash.

Terra Uranium has significantly expanded its land holdings in the Athabasca Basin through strategic option agreements with ATHA Energy Corp, setting the stage for a robust 2025 drilling campaign amid a recovering uranium market.

Latrobe Magnesium marks a year without lost time injuries and completes key construction phases, while navigating legal disputes and operational cost pressures.

Argenica Therapeutics has dosed 80% of patients in its Phase 2 stroke trial and gained FDA orphan drug designations for its second candidate, ARG-006. The company reports a cash-positive quarter with $15 million in reserves.

ioneer Ltd’s December 2024 quarterly cash flow report reveals ongoing cash outflows from operations and investing, with nearly $4.5 million spent this quarter but a solid cash reserve providing a runway of almost five quarters.

Alterity Therapeutics has announced encouraging Phase 2 trial results for ATH434, showing significant slowing of disease progression in multiple system atrophy (MSA) patients and a strong safety profile. These findings mark a potential breakthrough in treating a disease with no approved therapies.

Visionflex Group reported an 8% increase in Annual Recurring Revenue to $1.6 million in Q2 FY25 despite an 11% revenue decline, securing key contracts with Spark Health, BUPA, and Indigenous Wellness Connect. The company targets EBITDA profitability by Q4 FY25 amid a maturing sales pipeline.

NeuroScientific Biopharmaceuticals has initiated critical IND-enabling studies for its glaucoma drug candidate EmtinB, backed by a solid cash position of A$4.5 million as of December 2024. Preliminary melanin binding results are shaping the path toward first-in-human trials.

Imagion Biosystems has secured a AU$3 million capital injection and resumed its collaboration with Siemens, setting the stage to prioritize FDA filings and advance its MagSense® HER2 breast cancer imaging program.